Literature DB >> 24444033

Musashi1 regulates survival of hepatoma cell lines by activation of Wnt signalling pathway.

Kunlun Chen1, Qing Gao, Wei Zhang, Zhongwei Liu, Jiangyi Cai, Ying Liu, Jinkai Xu, Jie Li, Yi Yang, Xin Xu.   

Abstract

BACKGROUND & AIMS: Musashi1 (MSI1) belongs to the RNA-binding protein (RBP) family, with functions as translational activator or suppressor of specifically bound mRNA. However, its function in hepatocellular carcinoma (HCC) has been deeply unexplored. Here, we investigated the role of MSI1 for proliferation and tumourigenesis in HCC.
METHODS: The expression of MSI1 in HCC tissues was examined by immunohistochemistry and western blotting. The effects of MSI1 overexpression and silencing on cell proliferation, cell viability, tumoursphere and tumour formation of HCC were explored.
RESULTS: In this study, we initially reported that MSI1 was upregulated in HCC. Overexpression of MSI1 in HepG2 cell lines resulted in significantly promoted cell growth, tumour formation and cell cycle progression. Consistently, knockdown of MSI1 in Huh7 cell lines remarkably inhibited cell growth and tumour formation, and caused cell cycle arrest at the G1/S transition. Dual-luciferase assays indicated that MSI1 activated Wnt signal pathway, and APC and DKK1 were direct targets of MSI1.
CONCLUSION: Taken together, these findings indicate that an oncogenic role of MSI1 in HCC may be through modulation of cell growth and cell cycle by activating Wnt pathway via direct downregulation of APC and DKK1.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  MSI1; Wnt signalling pathway; cell growth; hepatoma

Mesh:

Substances:

Year:  2014        PMID: 24444033     DOI: 10.1111/liv.12458

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

Review 1.  Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets.

Authors:  Alexander E Kudinov; John Karanicolas; Erica A Golemis; Yanis Boumber
Journal:  Clin Cancer Res       Date:  2017-01-31       Impact factor: 12.531

2.  Luteolin inhibits Musashi1 binding to RNA and disrupts cancer phenotypes in glioblastoma cells.

Authors:  Caihong Yi; Guiming Li; Dmitri N Ivanov; Zhonghua Wang; Mitzli X Velasco; Greco Hernández; Soni Kaundal; Johanna Villarreal; Yogesh K Gupta; Mei Qiao; Christopher G Hubert; Matthew J Hart; Luiz O F Penalva
Journal:  RNA Biol       Date:  2018-11-18       Impact factor: 4.652

3.  Overexpression of Musashi-1 protein is associated with progression and poor prognosis of gastric cancer.

Authors:  Zhangxuan Shou; Xue Jin; Xujun He; Zhongsheng Zhao; Yuan Chen; Meihua Ye; Jiong Yao
Journal:  Oncol Lett       Date:  2017-03-21       Impact factor: 2.967

4.  Musashi-1 regulates AKT-derived IL-6 autocrinal/paracrinal malignancy and chemoresistance in glioblastoma.

Authors:  Hsiao-Yun Chen; Liang-Ting Lin; Mong-Lien Wang; Shu-Hsien Lee; Ming-Long Tsai; Chi-Chang Tsai; Wei-Hsiu Liu; Tzu-Chien Chen; Yi-Ping Yang; Yi-Yen Lee; Yuh-Lih Chang; Pin-I Huang; Yi-Wei Chen; Wen-Liang Lo; Shih-Hwa Chiou; Ming-Teh Chen
Journal:  Oncotarget       Date:  2016-07-05

5.  Dickkopf-1 contributes to hepatocellular carcinoma tumorigenesis by activating the Wnt/β-catenin signaling pathway.

Authors:  Rui Zhang; Hao-Ming Lin; Ruth Broering; Xiang-de Shi; Xian-Huan Yu; Lei-Bo Xu; Wen-Rui Wu; Chao Liu
Journal:  Signal Transduct Target Ther       Date:  2019-12-06

6.  Upregulation of musashi1 increases malignancy of hepatocellular carcinoma via the Wnt/β-catenin signaling pathway and predicts a poor prognosis.

Authors:  Qiuhua Liu; Cuijie Zhou; Bo Zhang
Journal:  BMC Gastroenterol       Date:  2019-12-30       Impact factor: 3.067

7.  Interplay among p21Waf1/Cip1, MUSASHI-1 and Krüppel-like factor 4 in activation of Bmi1-CreER reserve intestinal stem cells after gamma radiation-induced injury.

Authors:  Emilia J Orzechowska; Takahito Katano; Agnieszka B Bialkowska; Vincent W Yang
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.